

DÃ©la Golshayan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/302076/publications.pdf>

Version: 2024-02-01

84
papers

2,967
citations

201385

27
h-index

174990

52
g-index

88
all docs

88
docs citations

88
times ranked

4842
citing authors

#	ARTICLE	IF	CITATIONS
1	The Rational Use of Complement Inhibitors in Kidney Diseases. <i>Kidney International Reports</i> , 2022, 7, 1165-1178.	0.4	16
2	Impact of different urinary tract infection phenotypes within the first year post-transplant on renal allograft outcomes. <i>American Journal of Transplantation</i> , 2022, 22, 1823-1833.	2.6	15
3	Infection Risk in the First Year After ABO-incompatible Kidney Transplantation: A Nationwide Prospective Cohort Study. <i>Transplantation</i> , 2022, 106, 1875-1883.	0.5	7
4	Recurrence of IgA nephropathy after kidney transplantation: experience from the Swiss transplant cohort study. <i>BMC Nephrology</i> , 2022, 23, 178.	0.8	7
5	Pre-transplant Social Adaptability Index and clinical outcomes in renal transplantation: The Swiss Transplant Cohort study. <i>Clinical Transplantation</i> , 2021, 35, e14218.	0.8	1
6	Mutually exclusive lymphangiogenesis or perineural infiltration in human skin squamous-cell carcinoma. <i>Oncotarget</i> , 2021, 12, 638-648.	0.8	2
7	Infectious complications and graft outcome following treatment of acute antibody-mediated rejection after kidney transplantation: A nationwide cohort study. <i>PLoS ONE</i> , 2021, 16, e0250829.	1.1	4
8	Acute renal dysfunction after simultaneous pancreas-kidney transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 2610-2613.	2.6	0
9	Impact of Hyponatremia after Renal Transplantation on Decline of Renal Function, Graft Loss and Patient Survival: A Prospective Cohort Study. <i>Nutrients</i> , 2021, 13, 2995.	1.7	1
10	Regulation of Fibroblast Activation Protein-1 Expression: Focus on Intracellular Protein Interactions. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14028-14045.	2.9	10
11	Pre-transplant donor-specific HLA antibodies and risk for poor first-year renal transplant outcomes: results from the Swiss Transplant Cohort Study. <i>Transplant International</i> , 2021, 34, 2755-2768.	0.8	9
12	Use of induction therapy in pediatric heart transplant recipients in Switzerland – Analysis of the Swiss national database. <i>Transplant Immunology</i> , 2021, 68, 101443.	0.6	0
13	Management of allergy transfer upon solid organ transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 834-843.	2.6	8
14	Real-life food-safety behavior and incidence of foodborne infections in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2020, 20, 1424-1430.	2.6	8
15	Therapeutic Potential of Targeting Malt1-Dependent TCR Downstream Signaling to Promote the Survival of MHC-Mismatched Allografts. <i>Frontiers in Immunology</i> , 2020, 11, 576651.	2.2	2
16	Upfront use of eculizumab to treat early acute antibody-mediated rejection after kidney allotransplantation and relevance for xenotransplantation. <i>Xenotransplantation</i> , 2020, 27, e12630.	1.6	6
17	First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study. <i>American Journal of Transplantation</i> , 2020, 20, 2876-2882.	2.6	102
18	Dialysis after graft loss: a Swiss experience. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 2182-2190.	0.4	7

#	ARTICLE	IF	CITATIONS
19	Immunosuppression management in renal transplant recipients with normal-immunological risk: 10-year results from the Swiss Transplant Cohort Study. <i>Swiss Medical Weekly</i> , 2020, 150, w20354.	0.8	6
20	SARS-CoV-2 / COVID-19 in patients on the Swiss national transplant waiting list. <i>Swiss Medical Weekly</i> , 2020, 150, w20451.	0.8	1
21	Infection Ā SARS-CoV-2 et transplantation dĀ™organes solides. <i>Revue Medicale Suisse</i> , 2020, 16, 815-818.	0.0	0
22	Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 238-246.	2.6	5
23	Burden of endĀstage renal disease and evolving challenges in kidney transplantation. <i>Transplant International</i> , 2019, 32, 889-891.	0.8	7
24	Differential Effects of the Mitochondria-Active Tetrapeptide SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH ₂) and Its Peptidase-Targeted Prodrugs in Experimental Acute Kidney Injury. <i>Frontiers in Pharmacology</i> , 2019, 10, 1209.	1.6	14
25	Rituximab as monotherapy for the treatment of chronic active antibody-mediated rejection after kidney transplantation. <i>Transplant International</i> , 2018, 31, 451-455.	0.8	9
26	Targeted Ā-secretase inhibition of Notch signaling activation in acute renal injury. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, F736-F746.	1.3	6
27	SP695DIALYSIS AFTER GRAFT LOSS: THE SWISS EXPERIENCE. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i580-i581.	0.4	1
28	Acute Antibody-Mediated Rejection and its Treatment in Kidney Transplantation. <i>Transplantation</i> , 2018, 102, S93.	0.5	1
29	Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 9811-9840.	2.9	18
30	CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation. <i>Pharmacogenomics Journal</i> , 2017, 17, 69-75.	0.9	11
31	BK Polyomavirus-Specific 9mer CD8 T Cell Responses Correlate With Clearance of BK Viremia in Kidney Transplant Recipients: First Report From the Swiss Transplant Cohort Study. <i>American Journal of Transplantation</i> , 2017, 17, 2591-2600.	2.6	52
32	Fibroblast activation protein-Ā in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 977-991.	1.5	42
33	ExplorinG frailty and mild cognitive impairment in kidney transplantation to predict biomedical, psychosocial and health cost outcomes (GERAS): protocol of a nationwide prospective cohort study. <i>Journal of Advanced Nursing</i> , 2017, 73, 716-734.	1.5	6
34	IL-2-Mediated In Vivo Expansion of Regulatory T Cells Combined with CD154ĀCD40 Co-Stimulation Blockade but Not CTLA-4 Ig Prolongs Allograft Survival in Naive and Sensitized Mice. <i>Frontiers in Immunology</i> , 2017, 8, 421.	2.2	9
35	Update on Dendritic Cell-Induced Immunological and Clinical Tolerance. <i>Frontiers in Immunology</i> , 2017, 8, 1514.	2.2	83
36	Notch Antagonists: Potential Modulators of Cancer and Inflammatory Diseases. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7719-7737.	2.9	38

#	ARTICLE	IF	CITATIONS
37	Oral valganciclovir for CMV gastritis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, e50-e51.	0.7	1
38	Clinically-relevant threshold of preformed donor-specific anti-HLA antibodies in kidney transplantation. <i>Human Immunology</i> , 2016, 77, 483-489.	1.2	35
39	Polymorphisms in the lectin pathway of complement activation influence the incidence of acute rejection and graft outcome after kidney transplantation. <i>Kidney International</i> , 2016, 89, 927-938.	2.6	37
40	Mortality Prediction after the First Year of Kidney Transplantation: An Observational Study on Two European Cohorts. <i>PLoS ONE</i> , 2016, 11, e0155278.	1.1	12
41	All regulators great and small: when Treg need small RNAs to fulfill their commitment. <i>Transplant International</i> , 2015, 28, 1140-1142.	0.8	1
42	Additive effects of rapamycin and aspirin on dendritic cell allostimulatory capacity. <i>Immunopharmacology and Immunotoxicology</i> , 2015, 37, 434-441.	1.1	5
43	Targeted β -Secretase Inhibition To Control the Notch Pathway in Renal Diseases. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 8097-8109.	2.9	14
44	Potential and limitations of regulatory T-cell therapy in solid organ transplantation. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1197-1212.	1.3	12
45	Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity. <i>EMBO Journal</i> , 2014, 33, 2765-2781.	3.5	129
46	Lipoxin A4 Prevents the Progression of De Novo and Established Endometriosis in a Mouse Model by Attenuating Prostaglandin E2 Production and Estrogen Signaling. <i>PLoS ONE</i> , 2014, 9, e89742.	1.1	38
47	Phenytoin-associated severe hypocalcemia with seizures in a patient with a <i>TSC2-PKD1</i> contiguous gene syndrome. <i>Renal Failure</i> , 2013, 35, 866-868.	0.8	10
48	Enhanced and aberrant T cell trafficking following total body irradiation: a gateway to graft-versus-host disease?. <i>British Journal of Haematology</i> , 2013, 162, 808-818.	1.2	9
49	Potential of T-regulatory cells to protect xenografts. <i>Current Opinion in Organ Transplantation</i> , 2012, 17, 155-161.	0.8	18
50	MR imaging as a specific diagnostic tool for bilateral microcysts in chronic lithium nephropathy. <i>Kidney International</i> , 2012, 81, 601.	2.6	14
51	Potassium restores vasorelaxation of resistance arterioles in non-hypertensive DOCA/salt fed mice. <i>Microvascular Research</i> , 2012, 84, 340-344.	1.1	6
52	Therapeutic Efficacy of Polyclonal Tregs Does Not Require Rapamycin in a Low-Dose Irradiation Bone Marrow Transplantation Model. <i>Transplantation</i> , 2011, 92, 280-288.	0.5	27
53	Transplantation tolerance: Clinical potential of regulatory T cells. <i>Self/nonself</i> , 2011, 2, 26-34.	2.0	20
54	Immunosuppressive Effects of Streptozotocin-Induced Diabetes Result in Absolute Lymphopenia and a Relative Increase of T Regulatory Cells. <i>Diabetes</i> , 2011, 60, 2331-2340.	0.3	73

#	ARTICLE	IF	CITATIONS
55	Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation. <i>Journal of Clinical Investigation</i> , 2011, 121, 2794-2807.	3.9	86
56	Treg-Therapy Allows Mixed Chimerism and Transplantation Tolerance Without Cytoablative Conditioning. <i>American Journal of Transplantation</i> , 2010, 10, 751-762.	2.6	127
57	Differential Role of NaĀve and Memory CD4+ T-Cell Subsets in Primary Alloresponses. <i>American Journal of Transplantation</i> , 2010, 10, 1749-1759.	2.6	16
58	Anti-CD154 mAb and Rapamycin Induce T Regulatory Cell Mediated Tolerance in Rat-to-Mouse Islet Transplantation. <i>PLoS ONE</i> , 2010, 5, e10352.	1.1	42
59	Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. <i>European Heart Journal</i> , 2010, 31, 67-76.	1.0	71
60	Mycophenolic acid formulations in adult renal transplantation – update on efficacy and tolerability. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 341.	0.9	11
61	T regulatory cells in xenotransplantation. <i>Xenotransplantation</i> , 2009, 16, 121-128.	1.6	34
62	Oxidized LDL Modulates Apoptosis of Regulatory T Cells in Patients with ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1368-1384.	3.0	50
63	Transplantation tolerance induced by regulatory T cells: In vivo mechanisms and sites of action. <i>International Immunopharmacology</i> , 2009, 9, 683-688.	1.7	16
64	Regulation of Rat and Human T-Cell Immune Response by Pharmacologically Modified Dendritic Cells. <i>Transplantation</i> , 2009, 87, 1617-1628.	0.5	15
65	Optimal and continuous anaemia control in a cohort of dialysis patients in Switzerland. <i>BMC Nephrology</i> , 2008, 9, 16.	0.8	1
66	Tolerance-Inducing Immunosuppressive Strategies in Clinical Transplantation. <i>Drugs</i> , 2008, 68, 2113-2130.	4.9	46
67	Minimization of calcineurin inhibitors to improve long-term outcomes in kidney transplantation. <i>Transplant Immunology</i> , 2008, 20, 21-28.	0.6	32
68	Indoleamine 2,3-dioxygenase gene transfer prolongs cardiac allograft survival. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 293, H3415-H3423.	1.5	56
69	In vitroĀĀexpanded donor alloantigenĀĀ-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. <i>Blood</i> , 2007, 109, 827-835.	0.6	298
70	Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. <i>Blood</i> , 2007, 109, 2058-2065.	0.6	429
71	From current immunosuppressive strategies to clinical tolerance of allografts. <i>Transplant International</i> , 2007, 20, 12-24.	0.8	51
72	CD4+CD25+Foxp3+ regulatory T cells: from basic research to potential therapeutic use. <i>Swiss Medical Weekly</i> , 2007, 137, 625-34.	0.8	36

#	ARTICLE	IF	CITATIONS
73	In vitro expanded alloantigen-specific CD4+CD25+ regulatory T cell treatment for the induction of donor-specific transplantation tolerance. <i>International Immunopharmacology</i> , 2006, 6, 1879-1882.	1.7	18
74	A Novel Pathway of Antigen Presentation by Dendritic and Endothelial Cells: Implications for Allorecognition and Infectious Diseases. <i>Transplantation</i> , 2006, 82, S15-S18.	0.5	71
75	Drug-minimization or tolerance-promoting strategies in human kidney transplantation: is Campath-1H the way to follow?. <i>Transplant International</i> , 2006, 19, 881-884.	0.8	6
76	Phenotypic and genotypic risk factors for cardiovascular events in an incident dialysis cohort. <i>Kidney International</i> , 2006, 69, 1424-1430.	2.6	29
77	Achieving Permanent Survival of Islet Xenografts by Independent Manipulation of Direct and Indirect T-Cell Responses. <i>Diabetes</i> , 2005, 54, 1048-1055.	0.3	47
78	A Novel Pathway of Alloantigen Presentation by Dendritic Cells. <i>Journal of Immunology</i> , 2004, 173, 4828-4837.	0.4	293
79	Patient referral is influenced by dialysis centre structure in the Diamant Alpin Dialysis cohort study. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2341-2346.	0.4	24
80	Commentary: Priming of alloreactive T cells - where does it happen?. <i>European Journal of Immunology</i> , 2004, 34, 3301-3304.	1.6	8
81	The Diamant Alpin Dialysis cohort study: clinico-biological characteristics and cardiovascular genetic risk profile of incident patients. <i>Journal of Nephrology</i> , 2004, 17, 66-75.	0.9	9
82	Laparoscopic right nephrectomy for live kidney donation: functional results. <i>Transplant International</i> , 2003, 16, 419-424.	0.8	25
83	Laparoscopic right nephrectomy for live kidney donation: functional results. <i>Transplant International</i> , 2003, 16, 419-424.	0.8	8
84	Incidence and prognostic value of electrocardiographic abnormalities after heart transplantation. <i>Clinical Cardiology</i> , 1998, 21, 680-684.	0.7	36